| |
Join our trial design experts on Thursday, May 8 for an insightful webinar on the optimal use cases of master protocols in clinical trials. Register now.
|
|
Today’s Big NewsMay 1, 2025 |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
| By Nick Paul Taylor Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a delay to the expected approval of the vaccine in older adults. |
|
|
|
By Nick Paul Taylor Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off one-third of its staff to cut costs and extend its cash runway. |
By Gabrielle Masson Worldwide venture financing for the sector experienced a downturn from $8.1 billion in the first quarter of 2024 to $6.5 billion in 2025’s most recent quarter, GlobalData said in an April 30 release. |
By Nick Paul Taylor Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease. |
|
Get a head start on your IND submission. Lonza's rapid tox offering cuts toxicology material delivery times by up to 50%, overcoming critical bottlenecks. Learn how to streamline your development and hear about our new exciting offering for bispecifics in this webinar.
|
|
By Darren Incorvaia The National Institutes of Health is following in the FDA’s footsteps—away from animal testing. Announced April 29, the agency plans to establish a new office meant to develop nonanimal methods for biomedical research. |
By Darren Incorvaia Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 progressive multiple sclerosis trial, but the New York biotech is pointing to other measures from the study as reason to continue developing the asset. |
By Zoey Becker The company posted 6% revenue growth during the quarter thanks to three launches. Looking forward, Biogen said it's insulated from potential pharmaceutical tariffs. |
By Dave Muoio,Noah Tong,Emma Beavins,Anastassia Gliadkovskaya,Paige Minemyer President Donald Trump wrapped the first 100 days of his second term on April 29. With an unprecedented number of executive orders and other actions now under his belt, here's where his administration's health-focused efforts currently stand. |
By Angus Liu Moderna is extending its cost savings program into 2027 and targeting a cash breakeven point sometime in 2028 as the mRNA biotech faces multiple regulatory uncertainties around vaccines under the Trump administration. |
By Darren Incorvaia Bulgarian CRO Comac Medical has found a new leader to guide the company's international expansion. Chris Smyth, Ph.D., is leaving his post as president of Icon Biotech to take the helm at Comac Sept. 1, the company said in an April 28 release. |
By Eric Sagonowsky It's not immediately clear if COVID-19 vaccine makers could meet the agency's new requirement in order to release their updated vaccines by the time virus circulation typically ramps up in the fall and winter. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Available On-Demand Commissioning and qualification (C&Q) is vital within pharma manufacturing. View this valuable webinar on-demand to explore key strategies for effective management of systems, equipment and processes to ensure product safety, regulatory compliance, operational efficiency and overall quality assurance.
|
|
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| |
|
